JP2019527037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527037A5 JP2019527037A5 JP2018564409A JP2018564409A JP2019527037A5 JP 2019527037 A5 JP2019527037 A5 JP 2019527037A5 JP 2018564409 A JP2018564409 A JP 2018564409A JP 2018564409 A JP2018564409 A JP 2018564409A JP 2019527037 A5 JP2019527037 A5 JP 2019527037A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- smarca2
- level
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 63
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims 45
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims 45
- 230000014509 gene expression Effects 0.000 claims 39
- 239000003112 inhibitor Substances 0.000 claims 39
- 206010028980 Neoplasm Diseases 0.000 claims 36
- 239000003814 drug Substances 0.000 claims 35
- 201000011510 cancer Diseases 0.000 claims 34
- 230000011987 methylation Effects 0.000 claims 29
- 238000007069 methylation reaction Methods 0.000 claims 29
- 108090000623 proteins and genes Proteins 0.000 claims 27
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 12
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 claims 12
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 108700028341 SMARCB1 Proteins 0.000 claims 8
- 101150008214 SMARCB1 gene Proteins 0.000 claims 8
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 7
- 206010017758 gastric cancer Diseases 0.000 claims 7
- 201000011549 stomach cancer Diseases 0.000 claims 7
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 6
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims 6
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 102100037516 Protein polybromo-1 Human genes 0.000 claims 6
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 6
- 102100024793 SWI/SNF complex subunit SMARCC1 Human genes 0.000 claims 6
- 102100024790 SWI/SNF complex subunit SMARCC2 Human genes 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 201000005292 ovarian small cell carcinoma Diseases 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 102100023157 AT-rich interactive domain-containing protein 2 Human genes 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 101000685261 Homo sapiens AT-rich interactive domain-containing protein 2 Proteins 0.000 claims 4
- 101000601770 Homo sapiens Protein polybromo-1 Proteins 0.000 claims 4
- 101000687718 Homo sapiens SWI/SNF complex subunit SMARCC1 Proteins 0.000 claims 4
- 101000687720 Homo sapiens SWI/SNF complex subunit SMARCC2 Proteins 0.000 claims 4
- 101000835860 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Proteins 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 108010047956 Nucleosomes Proteins 0.000 claims 4
- 208000036822 Small cell carcinoma of the ovary Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 210000001623 nucleosome Anatomy 0.000 claims 4
- 238000007634 remodeling Methods 0.000 claims 4
- 230000004043 responsiveness Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 238000003364 immunohistochemistry Methods 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 claims 2
- LHGUZCKPFXXVPV-UHFFFAOYSA-N 1-[1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide Chemical compound C1CN(S(=O)(=O)CC)CCC1C(C)N1C2=CC=CC=C2C(C(=O)NCC=2C(NC(C)=CC=2OC)=O)=C1C LHGUZCKPFXXVPV-UHFFFAOYSA-N 0.000 claims 2
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 102100037151 Barrier-to-autointegration factor Human genes 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 238000001353 Chip-sequencing Methods 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- ULNXAWLQFZMIHX-UHFFFAOYSA-N GSK343 Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=C(N=CC=2)N2CCN(C)CC2)C(C)C)=C1CCC ULNXAWLQFZMIHX-UHFFFAOYSA-N 0.000 claims 2
- 101000740067 Homo sapiens Barrier-to-autointegration factor Proteins 0.000 claims 2
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 101710136946 Protein polybromo-1 Proteins 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 101710169053 SWI/SNF complex subunit SMARCC1 Proteins 0.000 claims 2
- 101710169052 SWI/SNF complex subunit SMARCC2 Proteins 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000000121 hypercalcemic effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 2
- HRDQQHUKUIKFHT-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-methyl-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylindole-4-carboxamide Chemical compound C1=C2N(C(C)C)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCN(C)CC1 HRDQQHUKUIKFHT-UHFFFAOYSA-N 0.000 claims 2
- HPODOLXTMDHLLC-QGZVFWFLSA-N n-[(4-methoxy-6-methyl-2-oxo-1h-pyridin-3-yl)methyl]-2-methyl-1-[(1r)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C3=CC=CC=C3N([C@H](C)C3CCN(CC(F)(F)F)CC3)C=2C)=C1OC HPODOLXTMDHLLC-QGZVFWFLSA-N 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 150000003384 small molecules Chemical group 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000011223 gene expression profiling Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 238000003196 serial analysis of gene expression Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347436P | 2016-06-08 | 2016-06-08 | |
| US62/347,436 | 2016-06-08 | ||
| PCT/US2017/036515 WO2017214373A1 (en) | 2016-06-08 | 2017-06-08 | Diagnostic and therapeutic methods for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527037A JP2019527037A (ja) | 2019-09-26 |
| JP2019527037A5 true JP2019527037A5 (enExample) | 2020-07-27 |
Family
ID=59325632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564409A Pending JP2019527037A (ja) | 2016-06-08 | 2017-06-08 | がんのための診断及び治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200129519A1 (enExample) |
| EP (1) | EP3469099A1 (enExample) |
| JP (1) | JP2019527037A (enExample) |
| CN (1) | CN109312407A (enExample) |
| WO (1) | WO2017214373A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| CN110366413A (zh) * | 2017-02-02 | 2019-10-22 | Epizyme股份有限公司 | 癌症治疗形式 |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
| US20220154295A1 (en) * | 2019-03-27 | 2022-05-19 | The Johns Hopkins University | Methods and materials for assessing and treating cancer |
| CN111849866B (zh) * | 2020-07-15 | 2022-06-24 | 华南农业大学 | H3K27me3调控FoxO1基因表达在猪卵巢颗粒细胞中的应用 |
| CN112904006B (zh) * | 2021-01-28 | 2022-12-27 | 中山大学 | 一种乳腺癌预后预测分子标志物及其应用 |
| KR20240052015A (ko) * | 2021-09-28 | 2024-04-22 | 폴 슈레 앙스띠뛰 | Cck2-r을 표적화하는 화합물을 사용한 치료 및/또는 영상화에 대한 암으로 진단된 환자의 반응을 예측하는 방법, 및 암을 선택적으로 치료 및/또는 영상화하는 방법에서 사용하기 위한 화합물 |
| JP2023082308A (ja) * | 2021-12-02 | 2023-06-14 | 国立大学法人 長崎大学 | スクリーニング方法、環状ペプチドおよびこれを含む癌細胞増殖抑制剤 |
| DE102022112378B4 (de) * | 2022-05-17 | 2024-02-15 | Abberior Instruments Gmbh | Verfahren, lichtmikroskop und computerprogramm zur bestimmung eines referenzzeitpunktes |
| KR102930473B1 (ko) * | 2022-11-22 | 2026-02-26 | 주식회사 네오나 | Gas5 억제제 및 smarca4 억제제를 유효성분으로 포함하는 간암 예방 또는 치료용 약학 조성물 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| KR100441557B1 (ko) | 1994-07-21 | 2005-08-05 | 아크조 노벨 엔.브이. | 고리형케톤과산화물조성물 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| US20140296248A1 (en) * | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| KR20190105669A (ko) * | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| WO2014176047A1 (en) * | 2013-04-25 | 2014-10-30 | Novartis Ag | Markers for ezh2 inhibitors |
| TW201718598A (zh) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US20180296563A1 (en) * | 2015-09-25 | 2018-10-18 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor |
| US20190038633A1 (en) * | 2016-02-08 | 2019-02-07 | Epizyme, Inc. | Methods of treating cancer |
-
2017
- 2017-06-08 CN CN201780035692.5A patent/CN109312407A/zh active Pending
- 2017-06-08 WO PCT/US2017/036515 patent/WO2017214373A1/en not_active Ceased
- 2017-06-08 US US16/305,708 patent/US20200129519A1/en not_active Abandoned
- 2017-06-08 JP JP2018564409A patent/JP2019527037A/ja active Pending
- 2017-06-08 EP EP17739384.0A patent/EP3469099A1/en not_active Withdrawn
-
2021
- 2021-07-08 US US17/370,721 patent/US20210338684A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy | |
| CN109790582B (zh) | 基于c-maf状态的乳腺癌治疗性治疗 | |
| Allen et al. | A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1 | |
| US10837966B2 (en) | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses | |
| US9880171B2 (en) | iASPP phosphorylation and metastatic potential | |
| JP2016105731A5 (enExample) | ||
| WO2016057367A1 (en) | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response | |
| Zhao et al. | Ubiquitin D is an independent prognostic marker for survival in stage IIB–IIC colon cancer patients treated with 5‐fluoruracil‐based adjuvant chemotherapy | |
| Sakellakis et al. | Patterns of indolence in prostate cancer | |
| Wang et al. | HMGB1-containing nucleosome mediates chemotherapy-induced metastasis of human lung cancer | |
| Rásó | Splice variants of RAS—translational significance | |
| AU2021203352A1 (en) | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof | |
| Szweda et al. | Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology | |
| JP7249044B2 (ja) | 腫瘍細胞の悪性化抑制剤及び抗腫瘍剤 | |
| Yang et al. | The clinicopathological features of BRAF mutated papillary thyroid cancers in Chinese patients | |
| JP2015525881A (ja) | 乳癌における予測マーカーとしてのＥＲα／Ｓｒｃ／ＰＩ３Ｋ複合体の検出 | |
| Uhlig et al. | Diagnostic and prognostic role of pancreatic secretory granule membrane major glycoprotein 2 (GP2) immunohistochemistry: A TMA study on 27,681 tumors | |
| Abodunrin et al. | Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges | |
| Baretti et al. | Precision cancer trials with immunomodulatory agents: personalizing histology agnostic approaches | |
| Giusti et al. | Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype | |
| US20250197924A1 (en) | Methods for selection and combination of sequencing results from biological samples for neoantigen scoring | |
| Gay et al. | PALB2 reversion mutations in breast, prostate, and ovarian carcinomas | |
| Ziprin et al. | 24. KRAS and BRAF mutations are rare in anal squamous cell carcinoma, justifying the use of EGFR targeted therapies | |
| Losada | Low Cohesive Gastric Cancer of the Antrum and Duodenum. Multi-omics analysis Can it Im-prove Treatment | |
| RU2018130764A (ru) | Стресс эндоплазматического ретикулума как прогностический инструмент в терапии рака и комбинированная терапия для лечения рака |